SOURCE: MorphoSys AG

February 24, 2011 01:24 ET

MorphoSys Announces Change in Executive Management Board

MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - February 24, 2011) -

MorphoSys AG /

MorphoSys Announces Change in Executive Management Board

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

Jens Holstein to succeed Dave Lemus as Chief Financial Officer

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that Jens Holstein, currently Regional CFO for the region EME (Europe/Middle East) of Fresenius Kabi AG and Managing Director of Fresenius Kabi Deutschland GmbH, will succeed Dave Lemus both as Chief Financial Officer of MorphoSys AG and as a member of the executive management board (Vorstand). Mr. Lemus will step down from his position as CFO with the Company in March 2011 to pursue other opportunities. Mr. Holstein will take up his position on May 1, 2011.

Dr. Gerald Möller, Chairman of the Supervisory Board of MorphoSys AG, commented: "On behalf of both the Supervisory Board and the Executive Management Board, I would like to express my heartfelt thanks to Dave Lemus for his commitment to helping build MorphoSys over the past thirteen years. His contributions have been central in making the Company as successful as it is today. We wish him all the very best for the future."

Dave Lemus has been Chief Financial Officer of MorphoSys AG since February 1998. After taking the Company public in 1999, Mr. Lemus held responsibility for a variety of areas including corporate development, corporate communications and legal.

"It's been a privilege to have accompanied MorphoSys's rise over the last decade, and to participate in its development into one of Europe's leading life science companies," commented Dave Lemus. "I leave a Company on a sound footing, both operationally and financially, and I remain very optimistic about MorphoSys's future prospects."

Dr. Möller continued: "We are delighted to be able to welcome an outstanding successor in Jens Holstein, who will be a key member of the executive management board of MorphoSys. Mr. Holstein has an exceptional track record and brings international business experience, which will be important for the Company as it continues its growth as one of Europe's leading biopharmaceutical companies."

Jens Holstein has served in a variety of financial and general management positions at Fresenius since joining in 1995. From 2006 until 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Finance Director and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent six years in the consulting industry, with positions in Frankfurt and London.

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

--- End of Message ---

MorphoSys AG

Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Press Release:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


Contact Information

  • For more information, please contact:

    MorphoSys AG
    Dr. Claudia Gutjahr-Loser
    Head of Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-122

    Mario Brkulj
    Senior Manager Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-454

    Jessica Kulpi
    Specialist Corporate Communications & IR
    Tel: +49 (0) 89 / 899 27-332

    Email Contact